Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BIO-TECHNE Corp (TECH) vs Tyson Foods, Inc. (TSN) Price & Performance

BIO-TECHNE CorpTrade
Tyson Foods, Inc.Trade

Price performance (Past 24H)

Key statistics

BIO-TECHNE Corp vs Tyson Foods, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Tyson Foods, Inc. trades at $52.15 (market cap $18.39B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays the higher dividend (3.9%). Which is the better fit depends on your goals.

TECHTSN
Market Cap
$11.34B$18.39B
Sector
HealthConsumer Staples
52-Week High
$72.48$68.75
52-Week Low
$43.31$50.72
Enterprise Value
$11.36B$25.66B
Dividend Yield
0.44%3.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.

The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.

Tyson Foods, Inc.

Tyson Foods (TSN) trades at $52.28, up 1.67% today, but faces bearish technical signals with the stock trading near key support levels. The company reported mixed quarterly results with two beats and one miss in recent quarters, while maintaining modest profitability with 1.03% net margins. Recent news highlights ongoing fraud investigations and reduced 2026 revenue guidance due to beef segment pressures, creating investor uncertainty despite continued institutional buying interest.

The outlook remains cautious with Wall Street maintaining a $69 price target but technical indicators signaling bearish momentum. Investment opportunity exists in the discounted valuation (P/S 0.33) if operational improvements materialize, though risks include ongoing legal scrutiny, commodity price volatility, and execution challenges in the beef business that could pressure near-term performance.

Returns comparison

Trailing returns across standard periods

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH

About Tyson Foods, Inc.

Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.

Read more on TSN